1. Home
  2. KALA vs ICCC Comparison

KALA vs ICCC Comparison

Compare KALA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

N/A

Current Price

$0.46

Market Cap

13.3M

Sector

Health Care

ML Signal

N/A

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$9.88

Market Cap

93.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KALA
ICCC
Founded
2009
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3M
93.1M
IPO Year
2017
1995

Fundamental Metrics

Financial Performance
Metric
KALA
ICCC
Price
$0.46
$9.88
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $31.50
N/A
AVG Volume (30 Days)
★ 285.9K
12.4K
Earning Date
04-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 67.39
53.85
EPS
N/A
★ 0.41
Revenue
N/A
★ $26,493,169.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$24.21
Revenue Growth
N/A
★ 51.64
52 Week Low
$0.07
$4.52
52 Week High
$3.96
$12.10

Technical Indicators

Market Signals
Indicator
KALA
ICCC
Relative Strength Index (RSI) 34.55 41.20
Support Level $0.35 $9.39
Resistance Level $0.72 $10.16
Average True Range (ATR) 0.05 0.27
MACD 0.01 0.03
Stochastic Oscillator 27.11 32.86

Price Performance

Historical Comparison
KALA
ICCC

About KALA KALA BIO Inc.

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: